Skip to main content
OpenTrials
Completed

NCT Number: NCT04588649

The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke

Stroke can lead to signficiant neurological deficits, and about one-third of stroke patients will be diagnosed of vascular mild cognitive impairment or post-stroke dementia. Post-stroke dementia includes all types of dementia that happen after stroke, irrespective of their cause, and vascular dementia (VaD), degenerative dementia (especially Alzheimer's disease), or mixed dementia (dementia as a result of the coexistence of vascular lesions of the brain and neurodegenerative lesions) are the most common causes of post-stroke dementia. However, it is difficult to determine to what extent cognitive impairment may be attributable to stroke versus concomitant Alzheimer disease. With the advent of PET imaging technique, we are able to conduct a multi-modal neuroimaging study to explore the composite influence of vascular injury, amyloid plaque and Tau protein the the cognitive performance after stroke.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-stroke Dementia Vascular Mild Cognitive Impairment

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Neurology, Chang-Gung memorial Hospital

Taoyuan, Guishan, 333, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for stroke/TIA patients

  • Males or females with age >= 50 years old
  • Having cerebral stroke or transient ischemic attack
  • Modified Rankin Scale < 4
  • Ability to participate in cognitive and neuroimaging assessments
  • Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
  • Provision of signed informed consent

Inclusion criteria

for healthy elderly controls

  • Males or females with age >= 50 years old
  • Without history of cerebral stroke or transient ischemic attack
  • Ability to participate in cognitive and neuroimaging assessments
  • Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
  • Provision of signed informed consent

Exclusion criteria

Exclusion criteria

for all subjects

  • Presence of dementia diagnosis before the index stroke or at the initial screening History of vascular MCI (VaMCI)
  • The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score >=104 [24] at the initial screening.
  • Presence of large infarction or lobar encephalomalacia on brain CT or MRI.
  • Severe language impairment precluding cognitive assessments, defined as a score of 3 points in the language score of the National Institute of Health Stroke Scale.
  • Life expectancy less than 1 year.
  • Clinically significant abnormal laboratory values.
  • Clinically significant or unstable medical or psychiatric illness.
  • Epilepsy history.
  • Cognitive impairment resulting from trauma or brain damage.
  • Substance abuse or alcoholism in the past 1 year
  • General MRI, and / or PET exclusion criteria.
  • Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
  • History of allergy to 18F-labelled radionucleic agents, [18F]AV-45 or [18F]THK-5351.
  • Subjects having high risks for the study according to the PI discretion.

Treatment and study plan

THK-5351

Drug

[18F]THK-5351 PET Imaging

AV-45

Drug

[18F]AV-45 PET Imaging

Primary outcomes

  1. CDR score of cognition deteriorating group and stable group

    Time frame: through study completion, an average of 1.5 year

    The CDR is a 5-point scale (0、0.5、1、2、3) used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. The necessary information to make each rating is obtained through a semi-structured interview of the patient and a reliable informant or collateral source (e.g., family member).

    Global score 0 = Normal、0.5 = Very Mild Dementia、1 = Mild Dementia、2 = Moderate Dementia、3 = Severe Dementia. The cognition deteriorating group is defined as CDR score declines from 0 or 0.5 at Month 3 to >=1 at Month 18. The cognition stable group is defined as CDR score remains at 0 or 0.5 at Month 18.

  2. Imaging positive and negative conditions

    Time frame: through study completion, an average of 1.5 year

    PET images are visually assessed by independent raters, who are nuclear medicine doctors and blinded to all clinical and diagnostic information. The raters classify each scan as 0-1 (no significant uptake)、2 (suspicious uptake)、3-4 (significant uptake). The score >= 2 is deemed as positive condition.

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2019
First posted
Oct 19, 2020
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.